| Characteristic | All patients (n = 10 745) | Primary prevention (n = 9568) | Secondary prevention (n = 1177) | |||
|---|---|---|---|---|---|---|
| Underwent anticoagulation therapy | Did not undergo therapy | Underwent anticoagulation therapy | Did not undergo therapy | Underwent anticoagulation therapy | Did not undergo therapy | |
| Participants, no. (%) | 7358 (68.5) | 3387 (31.5) | 6497 (67.9) | 3071 (32.1) | 861 (73.2) | 316 (26.8) |
| Age, yr, median (IQR) | 74 (17) | 70 (27) | 74 (18) | 68 (27) | 78 (14) | 83 (15) |
| Male sex, no. (%) | 4149 (56.4) | 1785 (52.7) | 3710 (57.1) | 1638 (53.3) | 439 (51.0) | 147 (46.5) |
| Hypertension, no. (%) | 3461 (47.0) | 1333 (39.4) | 2991 (46.0) | 1168 (38.0) | 470 (54.6) | 165 (52.2) |
| Diabetes, no. (%) | 1833 (24.9) | 645 (19.0) | 1585 (24.4) | 546 (17.8) | 248 (28.8) | 99 (31.3) |
| Ischemic stroke and/or transient ischemic attack, no. (%) | 843 (11.5) | 301 (8.9) | 0 | 0 | 843 (97.9) | 301 (95.3) |
| Ischemic stroke, no. (%) | 561 (7.6) | 186 (5.5) | 0 | 0 | 561 (65.2) | 186 (58.9) |
| Hemorrhagic stroke, no. (%) | 34 (0.5) | 25 (0.7) | 0 | 0 | 34 (3.9) | 25 (7.9) |
| CHADS 2 score, no. (%) | ||||||
| 0 | 1553 (21.1) | 1140 (33.7) | 1551 (23.9) | 1138 (37.1) | 2 (0.2) | 2 (0.6) |
| 1 | 2550 (34.7) | 1089 (32.2) | 2544 (39.2) | 1082 (35.2) | 6 (0.7) | 7 (2.2) |
| 2 | 2029 (27.6) | 709 (20.9) | 1935 (29.8) | 672 (21.9) | 94 (10.9) | 37 (11.7) |
| 3 | 795 (10.8) | 266 (7.9) | 445 (6.8) | 168 (5.5) | 350 (40.7) | 98 (31.0) |
| 4 | 354 (4.8) | 153 (4.5) | 22 (0.3) | 11 (0.4) | 332 (38.6) | 142 (44.9) |
| 5 | 76 (1.0) | 27 (0.8) | 0 | 0 | 76 (8.8) | 27 (8.5) |
| 6 | 1 (0) | 3 (0) | 0 | 0 | 1 (0) | 3 (0.9) |
Note: CHADS2 = congestive heart failure, hypertension, age ≥ 75 yr, diabetes mellitus and prior stroke or transient ischemic attack, IQR = interquartile range.